Scientists Discover New Cancer Target That Could Transform Immunotherapy
Researchers mapped cancer surface proteins across 85 patient samples, identifying FAT2 as a promising target for CAR-T cell therapy.
Summary
Scientists created the first comprehensive map of surface proteins across multiple cancer types using 85 patient-derived samples. They identified FAT2, a protein highly expressed on squamous cancers but barely present in healthy tissue, as a promising therapeutic target. Laboratory studies showed FAT2 is essential for cancer cell growth and adhesion. When researchers engineered immune cells (CAR-T cells) to target FAT2, these cells successfully attacked cancer in laboratory tests. This discovery could lead to more precise immunotherapies with fewer side effects, as targeting proteins unique to cancer cells should spare healthy tissue from damage.
Detailed Summary
Cancer immunotherapy has shown remarkable promise, but finding the right targets on cancer cells remains challenging. Most surface proteins targeted by current therapies are also found on healthy cells, causing significant side effects. This groundbreaking study addresses this limitation by creating the most comprehensive map of cancer surface proteins to date.
Researchers analyzed 85 patient-derived cancer samples using advanced N-glycoproteomics technology, which specifically identifies proteins on cell surfaces. They developed a systematic approach called Glyco PDXplorer to catalog thousands of surface proteins across different cancer types and compare them to normal tissue expression patterns.
The team discovered FAT2, a surface protein highly enriched in squamous cancers (including head and neck cancers) but minimally present in healthy tissues. Laboratory experiments revealed that FAT2 plays crucial roles in cancer cell survival, growth, and adhesion by regulating cellular architecture and key signaling pathways. When researchers engineered CAR-T cells to specifically target FAT2, these modified immune cells demonstrated significant anti-tumor activity in laboratory models.
This research represents a major advance in precision cancer medicine. By identifying targets unique to cancer cells, treatments could become more effective while reducing the severe side effects that limit current immunotherapies. The comprehensive protein atlas created by this study also provides a valuable resource for discovering additional therapeutic targets across various cancer types.
While promising, this work remains in early stages. The findings need validation in human clinical trials, and researchers must determine optimal dosing and delivery methods. However, this systematic approach to target discovery could accelerate development of safer, more effective cancer treatments.
Key Findings
- FAT2 protein is highly expressed on squamous cancers but barely detectable in healthy tissue
- CAR-T cells engineered to target FAT2 showed significant anti-tumor activity in laboratory tests
- Comprehensive cancer surface protein atlas created from 85 patient samples enables target discovery
- FAT2 regulates cancer cell growth and adhesion through integrin-PI3K signaling pathways
Methodology
Researchers used N-glycoproteomics to analyze surface proteins in 85 patient-derived xenografts across multiple cancer types. They developed Glyco PDXplorer atlas and validated FAT2 through functional studies and CAR-T cell engineering experiments.
Study Limitations
Study conducted in laboratory models and patient-derived samples, requiring validation in human clinical trials. Long-term safety and efficacy of FAT2-targeted therapies remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.